SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC  20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported): March 14, 2006

 

Array BioPharma Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

000-31979

84-1460811

(State or Other Jurisdiction

(Commission

(IRS Employer

of Incorporation)

File Number)

Identification No.)

 

 

 

 

 

 

3200 Walnut Street, Boulder, Colorado

80301

(Address of Principal Executive Offices)

(Zip Code)

 

 

Registrant’s telephone number, including area code:    (303) 381-6600

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

        Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

        o                    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

        o                    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

        o                    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

        o                    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

ITEM 8.01. OTHER EVENTS

 

On March 14, 2006, Array BioPharma issued a press release announcing that a scientific poster on its KSP anti-cancer program will be presented at the 4th International Symposium on Targeted Anti-Cancer Therapies in Amsterdam, The Netherlands, the full text of which is attached hereto as Exhibit 99.1.

 

 

 

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

 

(c) Exhibits.

 

99.1         Press release dated March 14, 2006 entitled “Array BioPharma Announces KSP Anti-Cancer Program.”

 

2


 

SIGNATURES

                Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ARRAY BIOPHARMA INC.

 

 

 

Date: March 14, 2006

By:

/s/ Robert E. Conway

 

 

Robert E. Conway

 

 

Chief Executive Officer

 

 

3


 

EXHIBIT INDEX

 

Exhibit No.

 

99.1                                                Press release dated March 14, 2006 entitled “Array BioPharma Announces KSP Anti-Cancer Program.”

 

 

 

 

 

 

 

4